Patents by Inventor Fusheng ZHOU

Fusheng ZHOU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRIMIDINE-FUSED CYCLIC COMPOUND AND PREPARATION METHOD AND USE THEREOF
    Publication number: 20250186456
    Abstract: Provided are a pyrimidine-fused cyclic compound represented by formula (A) having an inhibitory effect on KRAS gene mutation, or a pharmaceutically acceptable salt, a stereoisomer or a solvate thereof, a pharmaceutical composition containing the compound, and an application thereof in the preparation of anticancer drugs.
    Type: Application
    Filed: August 31, 2022
    Publication date: June 12, 2025
    Applicants: Genfleet Therapeutics (Shanghai) Inc., ZHEJIANG GEN FLEET THERAPEUTICS CO., LTD.
    Inventors: Tao JIANG, Fusheng ZHOU, Tao LIANG, Leitao ZHANG, Lijian CAI, Zhubo LIU, Qi HUANG, Xiaoming XU, Jichen ZHAO, Yandong LU, Kai MA, Chonglan LIN, Jiong LAN
  • Pyrimidine Heterocyclic Compound, Preparation Method Thereof and use Thereof in Medicine
    Publication number: 20250145632
    Abstract: The present invention discloses a pyrimidine heterocyclic compound, and a preparation method and medical use thereof. Specifically, the present invention discloses a pyrimidine heterocyclic compound with a structure shown in Formula (A) or a pharmaceutically acceptable salt thereof (groups are each defined in the specification), a pharmaceutical composition comprising the compound, and use of the compound in treatment of cell proliferative diseases (such as cancers).
    Type: Application
    Filed: December 21, 2022
    Publication date: May 8, 2025
    Inventors: Hongfu LU, Jingjing PENG, Xiao DING, Jinxin LIU, Yingtao LIU, Feng REN, Fusheng ZHOU, Tao JIANG, Tao LIANG, Jiong LAN, Qiang LU
  • FUSED RING-SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF
    Publication number: 20250084078
    Abstract: Disclosed in the present invention is a compound as represented by formula (IA) or formula (IC) or a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof. The definition of each group in the formula is shown in the description for details. Further disclosed are a pharmaceutical composition containing the compound and the use thereof in the preparation of a drug for preventing and/or treating diseases or conditions related to HPK1 activity.
    Type: Application
    Filed: January 3, 2023
    Publication date: March 13, 2025
    Applicants: GENFLEFT THERAPEUTICS (SHANGHAI) INC., ZHEJIANG GENFLEFT THERAPEUTICS CO., LTD.
    Inventors: Jichen ZHAO, Fusheng Zhou, Chonglan LIN, Ling PENG, Wan HE, Huabin YANG, Zhen LI, Tao ZHANG, Kai MA, Jiong LAN, Qiang LU
  • POLYMORPH OF KRAS INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF
    Publication number: 20250051333
    Abstract: Provided are a polymorph of a KRAS inhibitor, a preparation method therefor, and a use thereof. Specifically disclosed is a pharmaceutically acceptable salt of a compound 1 or a polymorph of the compound or pharmaceutically acceptable salt thereof, and further disclosed are a preparation method for the salt or polymorph and an application of the salt or polymorph in the treatment and/or prevention of KRAS G12C mutation-related diseases.
    Type: Application
    Filed: December 23, 2022
    Publication date: February 13, 2025
    Applicants: GENFLEET THERAPEUTICS (SHANGHAI) INC., ZHEJIANG GENFLEET THERAPEUTICS CO., LTD.
    Inventors: Fusheng ZHOU, Jinzhu ZHAO, Yudong CAO, Lun XIONG, Rongzhen SHI, Jiong LAN
  • AROYL SUBSTITUTED TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF
    Publication number: 20240360154
    Abstract: Disclosed are an aroyl substituted tricyclic compound, a preparation method therefor and use thereof. Specifically, the aroyl substituted tricyclic compound of the present invention has a structure of formula (C), and has, as a BTK inhibitor, the advantages of high activity, good selectivity and low toxic and side effects.
    Type: Application
    Filed: September 21, 2021
    Publication date: October 31, 2024
    Inventors: Fusheng ZHOU, Tao JIANG, Yingtao LIU, Chonglan LIN, Leitao ZHANG, Zhubo LIU, Kai MA, Wan HE, Xiaoming XU, Lijian FENG, Xiaoling LAN, Qian DING, Qiang LV, Jiong LAN
  • CRYSTAL FORM OF RIPK1 INHIBITOR, ACID SALT THEREOF, AND CRYSTAL FORM OF ACID SALT THEREOF
    Publication number: 20240352040
    Abstract: Disclosed are a crystal form of a RIPK1 inhibitor, an acid salt thereof, and a crystal form of an acid salt thereof. The crystal form of the RIPK1 inhibitor, the acid salt thereof, and the crystal form of the acid salt thereof have advantages of good stability and low hygroscopicity, and same have good pharmaceutical prospects.
    Type: Application
    Filed: August 2, 2022
    Publication date: October 24, 2024
    Inventors: Fusheng ZHOU, Yuanzhi TAO, Jinzhu ZHAO, Jiong LAN
  • HETEROCYCLIC LACTAM COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF
    Publication number: 20240294523
    Abstract: Disclosed is a heterocyclic lactam compound or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, as represented in formula (I), wherein the compounds have an inhibitory effect on RIPK1 and the definition of each group in the formula is detailed in the description. In addition, further disclosed are a pharmaceutical composition containing the compound, and the use thereof in the preparation of a drug for treating RIPK1-related diseases or conditions.
    Type: Application
    Filed: June 10, 2022
    Publication date: September 5, 2024
    Applicants: Genfleet Therapeutics (Shanghai) Inc., ZHEJIANG GENFLEET THERAPEUTICS CO., LTD.
    Inventors: Fusheng Zhou, Yingtao LIU, Xiaoming XU, Zhubo LIU, Jiong LAN
  • PYRIDINO-OR PYRIMIDO-CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF
    Publication number: 20240270758
    Abstract: Provided is a pyridino- or pyrimido-cyclic compound having an inhibitory effect on a KRAS gene mutation, or a pharmaceutically acceptable salt, a stereoisomer or a solvate thereof, wherein the structure of the compound is as shown in formula (AI) or (AII), and the definition of each group in the formula is detailed in the description. In addition, also disclosed are a pharmaceutical composition comprising the compound, and the use thereof in the preparation of a cancer drug.
    Type: Application
    Filed: April 29, 2022
    Publication date: August 15, 2024
    Inventors: Tao Jiang, Fusheng Zhou, Leitao Zhang, Lijian Cai, Xiaoming Xu, Kai Ma, Zhubo Liu, Jiong Lan
  • Substituted heterocyclic fused cyclic compound, preparation method therefor and pharmaceutical use thereof
    Patent number: 12054497
    Abstract: A substituted heterocyclic fused cyclic compound as represented by formula (I) or formula (IA) and having a selective inhibitory effect on KRAS gene mutation, or a pharmaceutically-acceptable salt, a stereoisomer, a solvate or a prodrug thereof, a pharmaceutical composition containing the compound, and an application thereof in preparation of cancer drugs are provided.
    Type: Grant
    Filed: October 28, 2020
    Date of Patent: August 6, 2024
    Assignees: Genfleet Therapeutics (Shanghai)Inc., Zhejiang Genfleet Therapeutics Co., Ltd.
    Inventors: Fusheng Zhou, Tao Jiang, Chonglan Lin, Lijian Cai, Wan He, Jiong Lan
  • FUSED RING SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF
    Publication number: 20240182465
    Abstract: A compound having HPK1 inhibitory activity as shown in formula (IA) or (IC), and a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof, and a pharmaceutical composition containing the compound, and use of same in preparation of a drug for preventing and/or treating diseases or conditions associated with HPK1 activity.
    Type: Application
    Filed: March 3, 2022
    Publication date: June 6, 2024
    Applicants: GENFLEET THERAPEUTICS (SHANGHAI) INC., ZHEJIANG GENFLEET THERAPEUTICS CO., LTD.
    Inventors: Fusheng ZHOU, Jichen ZHAO, Wan HE, Chonglan LIN, Ling PENG, Huabin YANG, Zhen LI, Xiaoling LAN, Mei GE, Qian DING, Xiang YU, Jiong LAN, Qiang LU
  • PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF
    Publication number: 20240174691
    Abstract: Disclosed are a pyrimidine-fused cyclic compound having an inhibitory effect on KRAS gene mutation, or a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof, and a pharmaceutical composition containing the compound, and the use thereof in the preparation of a drug for treating cancer.
    Type: Application
    Filed: March 17, 2022
    Publication date: May 30, 2024
    Applicants: GENFLEET THERAPEUTICS (SHANGHAI) INC., ZHEJIANG GENFLEET THERAPEUTICS CO., LTD.
    Inventors: Tao JIANG, Fusheng ZHOU, Leitao ZHANG, Lijian CAI, Feng YAN, Jichen ZHAO, Jiong LAN, Qiang LU
  • SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF
    Publication number: 20240158417
    Abstract: A substituted heterocyclic fused cyclic compound as represented by formula (I) or formula (IA) and having a selective inhibitory effect on KRAS gene mutation, or a pharmaceutically-acceptable salt, a stereoisomer, a solvate or a prodrug thereof, a pharmaceutical composition containing the compound, and an application thereof in preparation of cancer drugs are provided.
    Type: Application
    Filed: October 17, 2023
    Publication date: May 16, 2024
    Applicants: GENFLEET THERAPEUTICS (SHANGHAI) INC., ZHEJIANG GENFLEET THERAPEUTICS CO.,LTD.
    Inventors: Fusheng ZHOU, Tao JIANG, Chonglan LIN, Lijian CAI, Wan HE, Jiong LAN
  • FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF
    Publication number: 20230203060
    Abstract: Provided are a fused tricyclic compound having the structure shown in formula (I), a pharmaceutical composition thereof, and a use thereof. The fused tricyclic compound serves as a selective inhibitor of KRAS mutation, and has high activity, good selectivity. and reduced toxic side effects.
    Type: Application
    Filed: May 27, 2021
    Publication date: June 29, 2023
    Inventors: Fusheng ZHOU, Tao JIANG, Yingtao LIU, Jichen ZHAO, Wan HE, Zhubo LIU, Ling PENG, Lijian CAI, Leitao ZHANG, Chonglan LIN, Huabin YANG, Tao ZHANG, Jiong LAN
  • DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF
    Publication number: 20230139111
    Abstract: Provided are a dihydronaphthyridinone compound as shown in formula (I), which compound has a selective inhibitory effect on RIPK1, and a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof. In addition, provided are a pharmaceutical composition containing the compound, and the use thereof in the preparation of a drug for treating RIPK1-related diseases or conditions.
    Type: Application
    Filed: February 9, 2021
    Publication date: May 4, 2023
    Applicants: GENFLEET THERAPEUTICS (SHANGHAI) INC., ZHEJIANG GENFLEET THERAPEUTICS CO., LTD.
    Inventors: Fusheng ZHOU, Xiaoming XU, Leitao ZHANG, Xin LI, Lili TANG, Jiong LAN
  • SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF
    Publication number: 20230084095
    Abstract: A substituted heterocyclic fused cyclic compound as represented by formula (I) or formula (IA) and having a selective inhibitory effect on KRAS gene mutation, or a pharmaceutically-acceptable salt, a stereoisomer, a solvate or a prodrug thereof, a pharmaceutical composition containing the compound, and an application thereof in preparation of cancer drugs are provided.
    Type: Application
    Filed: October 28, 2020
    Publication date: March 16, 2023
    Applicants: GENFLEET THERAPEUTICS (SHANGHAI) INC., ZHEJIANG GENFLEET THERAPEUTICS CO., LTD.
    Inventors: Fusheng ZHOU, Tao JIANG, Chonglan LIN, Lijian CAI, Wan HE, Jiong LAN
  • OXO SIX-MEMBERED CYCLOPYRIMIDINE COMPOUND, PREPARATION METHOD AND MEDICAL USE THEREOF
    Publication number: 20220363681
    Abstract: Provided is an oxygen-substituted six-membered ring pyrimidine compound with selective inhibitory effect on KRAS gene mutation and a pharmaceutically acceptable salt, a stereoisomer, a solvate, or a prodrug thereof, as represented by formula (I). The definition of each group or symbol in the formula is detailed in the specification. Moreover, a pharmaceutical composition containing the compound and an application thereof in the preparation of cancer drugs are also provided.
    Type: Application
    Filed: August 12, 2020
    Publication date: November 17, 2022
    Inventors: Fusheng ZHOU, Tao JIANG, Wan HE, Zhubo LIU, Leitao ZHANG, Jiong LAN
  • POLYMORPH OF CDK9 INHIBITOR AND PREPARATION METHOD FOR POLYMORPH AND USE THEREOF
    Publication number: 20220315576
    Abstract: The present invention provides a polymorph of a CDK9 inhibitor and a preparation method for the polymorph and use thereof. Specifically, disclosed are 4-(((4-(5-chloro-2-(((1R,4r)-4-(((R)-1-methoxypropyl-2-yl)amino)cyclohexyl)amino)pyridine-4-yl)thiazole-2-yl)amino)methyl)tetrahydro-2H-pyrano-4-methylnitrile maleate or fumarate or polymorphs thereof and applications thereof. In addition, also disclosed are a pharmaceutical composition containing the substance and an application of the pharmaceutical composition.
    Type: Application
    Filed: June 5, 2020
    Publication date: October 6, 2022
    Inventors: Fusheng ZHOU, Jinzhu ZHAO, Jiong LAN
  • OXAAZAQUINAZOLINE-7(8H)-KETONE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF
    Publication number: 20220251109
    Abstract: An oxaazaquinazolin-7(8H)-ketone compound with a selective inhibition effect on KRAS gene mutation and pharmaceutically acceptable salts thereof, stereoisomers, solvent compounds or prodrugs (as shown in formula I or formula II, see the details of the definition to each group in the formulas in the specification), as well as the pharmaceutical composition containing the compound, and the application thereof in preparation of cancer medicine.
    Type: Application
    Filed: April 28, 2020
    Publication date: August 11, 2022
    Applicants: GENFLEET THERAPEUTICS (SHANGHAI) INC., ZHEJIANG GENFLEET THERAPEUTICS CO., LTD.
    Inventors: Fusheng ZHOU, Lijian CAI, Tao JIANG, Jichen ZHAO, Yingtao LIU, Jinzhu ZHAO, Leitao ZHANG, Zhubo LIU, Ling PENG, Wan HE, Huabin YANG, Tao ZHANG, Qian DING, Biao ZHENG, Qiang LV, Jiong LAN
  • BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF
    Publication number: 20220235032
    Abstract: A substituted dihydropyrazole compound as shown in formula I, which compound has a selective inhibitory effect on RIPK1, and a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof, wherein the definition of each group in the formula is detailed in the description. In addition is a pharmaceutical composition containing the compound, and the use thereof in the preparation of a drug for treating RIPK1-related diseases or conditions.
    Type: Application
    Filed: May 9, 2020
    Publication date: July 28, 2022
    Applicants: GENFLEET THERAPEUTICS (SHANGHAI) INC., ZHEJIANG GENFLEET THERAPEUTICS CO., LTD.
    Inventors: Fusheng ZHOU, Xiaoming XU, Leitao ZHANG, Tao JIANG, Yingtao LIU, Jiong LAN
  • SUBSTITUTED HETEROCYCLIC AMIDE COMPOUND AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF
    Publication number: 20220177462
    Abstract: A substituted heterocyclic amide compound having a selective inhibitory effect on RIPK1, and a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof, and a pharmaceutical composition containing the compound, and the use of same in the preparation of a drug for treating a RIPK1-related diseases or conditions.
    Type: Application
    Filed: March 20, 2020
    Publication date: June 9, 2022
    Applicants: GENFLEET THERAPEUTICS (SHANGHAI) INC., ZHEJIANG GENFLEET THERAPEUTICS CO., LTD.
    Inventors: Fusheng ZHOU, Xiaoming XU, Leitao ZHANG, Zhubo LIU, Gang HU, Qian DING, Fubo XIE, Biao ZHENG, Qiang LV, Jiong LAN